Webinar Reducing Lentivirus Costs

Webinar Reducing Lentivirus Costs

Reducing Lentivirus Costs

Are you curious about how cost reductions in Cell & Gene Therapy manufacturing can be achieved? 

Key areas of focus include:

If you missed our recent webinar on Reducing Lentivirus Costs: A DOE Case Study, you can now watch the replay and gain valuable insights into cost-efficiency strategies for Cell & Gene Therapy manufacturing.

Lentiviral vectors (LV) play a critical role in CAR T therapies, but the high cost of plasmid DNA used in transfection-based production remains a significant challenge. During the webinar, Diederik Lokhorst, Viral Vector Specialist at NecstGen, shared how our team leverages Design of Experiments (DOE) to address this challenge, reduce the Cost of Goods (COG), and make lentivirus-based therapies more affordable.

What You’ll Learn in the Replay:
– An inside look at transfection-based lentivirus production

– ⁠DOE as a tool to understand and improve your manufacturing process

– ⁠A Case study applying DOE to reduce LV Manufacturing Costs for CAR T

If you have additional questions, we invite you to share your questions.

Webinar LV Process for CAR T

Webinar LV Process for CAR T

Transforming Your LV Process For CAR T

Shifting from traditional, ad hoc methodologies to a structured, data-based development approach to create a scalable, GMP-ready process

Key areas of focus include:

Transitioning from research to clinical application presents numerous challenges, particularly for CAR T developers, academic institutions, and small companies at a pivotal point in their development journey. This webinar is specifically designed to address these groups, aiming to refine their process development for clinical readiness. We will emphasise the need for a shift to a structured, data-driven methodology, crucial for meeting the stringent requirements of large-scale Good Manufacturing Practice (GMP).

Our objective?

To help you understand the necessity of shifting from traditional, ad hoc methodologies to a structured, data-based development approach. This segment emphasises the importance of embracing change and innovation to overcome the limitations of the “this is how we’ve always done it” mindset.

– Quality by Design (QbD): a systematic development framework
– Design of Experiments (DOE): understanding and improving your process
– Scalability: designing a process that can be scaled up from the bench to large, industrial scale
– USP & DSP: improving production and purification

Our expert can provide insights and answer your queries to advance your CAR T therapy development.

If you have additional questions, we invite you to share your questions.

Webinar CAR Therapy Today & Tomorrow

Webinar CAR Therapy Today & Tomorrow

CAR Therapy: Today & Tomorrow

Explore available CAR therapies, differentiation, development challenges, and lessons learned.

Key areas of focus include:

Would you like to familiarise yourself with CAR Therapies? Watch the replay to explore CAR-based Cell Therapy with our scientist, Somayeh Rezaeifard, elaborating on the various available CAR therapies, their differentiation, current challenges in therapy development, and lessons learned until today.

Whether you’re part of an academic research group, pioneering a new biotech, or working at a global CGT leader, this webinar brings together various aspects of CAR therapies to explore, discuss, and learn.

Key Learnings

  • Comprehensive overview of various CAR therapies
  • Breaking Down CAR Structure with comparison among CAR T, macrophages, and NK frameworks
  • Current CAR T status limitations in development and application
  • Critical factors that influence the quality of CAR therapy products
  • Lessons learned to guide new CAR-based therapy development

Join the conversation and equip yourself with the latest knowledge and insights in CAR-based immunotherapy.

Webinar Product Quality For Cell Therapies

Webinar Product Quality For Cell Therapies

Product Quality For Cell Therapies

This session is set to be a compelling exploration of product quality in Cell Therapies.

Key areas of focus include:

As the field of regenerative medicine and Cell Therapies advances, it underscores a longstanding imperative: the quality, safety, and efficacy of these products has always been and remains the most crucial aspect of any therapy.

While a multi-faceted approach to quality is a standard across various therapies, Cell Therapies present unique challenges due to their nature as living therapies. Specifications for these products will inherently exhibit a range because they are derived from living cells. Consequently, testing strategies for Cell Therapies are more risk-based and require a tailored approach when compared to non-Advanced Therapy Medicinal Products (non-ATMPs).

  • Understanding Cell Therapies
  • The Importance of Product Quality
  • Building a Quality Strategy
  • Testing and Validation
  • Regulatory Landscape

Our experts can provide insights and answer your queries to advance your cell therapy development. This webinar is designed to help you explore and navigate the complexities of product quality strategies for cell therapies. If you have additional questions, we invite you to share them.

Webinar iPSC Banking & Derivation

Webinar iPSC Banking & Derivation

iPSC Banking & Derivation

Ever wondered how to transition from bench to GMP suitable processes in the iPSC-derived therapies field? Yes? Watch the webinar replay on iPSC Derivation & Banking.

Key areas of focus include:

  • Transitioning from Bench to GMP Suitable Processes
  • Identifying Technologies for Scale-Up and Future Manufacturing
  • New GMP iPSC Generation
  • Master and Working Cell Bank Creation
  • Quality Control Strategies for Safe Products

Our experts can provide insights and answer your queries to advance your therapy development. This webinar is designed to help you explore and navigate the complexities of iPSC therapy development, but if you have additional questions, we invite you to ask us your questions.

NecstGen Services

Cell Therapy Development & Manufacturing

Viral Vector Development & Manufacturing

Cleanroom Rental

About Us

NecstGen is a non-profit CDMO and Centre of Excellence for Cell and Gene Therapy located in a purpose-built GMP facility in Leiden, The Netherlands. Dedicated to the field of Cell and Gene Therapies, we provide expertise and capacity.

NecstGen

Team

Partners

History

Facility

Ecosystem